Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo

Thomas S. Rector, Spencer H. Kubo, Jay N Cohn

Research output: Contribution to journalArticle

365 Citations (Scopus)

Abstract

Patients' perspectives concerning the effects of disease and therapy on their lives have become increasingly important for the assessment of medications in clinical trials. The Minnesota Living with Heart Failure (LIhiFE) questionnaire was developed to systematically and comprehensively assess the patient's perceptions of the effects of heart failure, and its treatment on his or her daily life.1 A valid measure of therapeutic response should be responsive to medications known to benefit patients with heart failure and be insensitive to the effects of placebo. In addition, a valid measure would indicate that patients with overt heart failure have more impairment than do those with left ventricular dysfunction who do not need medications for heart failure. We previously showed that this questionnaire was sensitive to the effects of pimobendan, an inotropic agent with vasodilator properties, and was insensitive to placebo in patients with moderate-to-severe heart failure.2,3 This report demonstrates the questionnaire's responsiveness to a converting enzyme inhibitor and confirms its insensitivity to placebo.

Original languageEnglish (US)
Pages (from-to)1106-1107
Number of pages2
JournalThe American journal of cardiology
Volume71
Issue number12
DOIs
StatePublished - May 1 1993

Fingerprint

Enalapril
Heart Failure
Placebos
Therapeutics
Placebo Effect
Left Ventricular Dysfunction
Enzyme Inhibitors
Vasodilator Agents
Surveys and Questionnaires
Clinical Trials

Cite this

Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. / Rector, Thomas S.; Kubo, Spencer H.; Cohn, Jay N.

In: The American journal of cardiology, Vol. 71, No. 12, 01.05.1993, p. 1106-1107.

Research output: Contribution to journalArticle

@article{98d42994e51a4064978e381279450e5c,
title = "Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo",
abstract = "Patients' perspectives concerning the effects of disease and therapy on their lives have become increasingly important for the assessment of medications in clinical trials. The Minnesota Living with Heart Failure (LIhiFE) questionnaire was developed to systematically and comprehensively assess the patient's perceptions of the effects of heart failure, and its treatment on his or her daily life.1 A valid measure of therapeutic response should be responsive to medications known to benefit patients with heart failure and be insensitive to the effects of placebo. In addition, a valid measure would indicate that patients with overt heart failure have more impairment than do those with left ventricular dysfunction who do not need medications for heart failure. We previously showed that this questionnaire was sensitive to the effects of pimobendan, an inotropic agent with vasodilator properties, and was insensitive to placebo in patients with moderate-to-severe heart failure.2,3 This report demonstrates the questionnaire's responsiveness to a converting enzyme inhibitor and confirms its insensitivity to placebo.",
author = "Rector, {Thomas S.} and Kubo, {Spencer H.} and Cohn, {Jay N}",
year = "1993",
month = "5",
day = "1",
doi = "10.1016/0002-9149(93)90582-W",
language = "English (US)",
volume = "71",
pages = "1106--1107",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo

AU - Rector, Thomas S.

AU - Kubo, Spencer H.

AU - Cohn, Jay N

PY - 1993/5/1

Y1 - 1993/5/1

N2 - Patients' perspectives concerning the effects of disease and therapy on their lives have become increasingly important for the assessment of medications in clinical trials. The Minnesota Living with Heart Failure (LIhiFE) questionnaire was developed to systematically and comprehensively assess the patient's perceptions of the effects of heart failure, and its treatment on his or her daily life.1 A valid measure of therapeutic response should be responsive to medications known to benefit patients with heart failure and be insensitive to the effects of placebo. In addition, a valid measure would indicate that patients with overt heart failure have more impairment than do those with left ventricular dysfunction who do not need medications for heart failure. We previously showed that this questionnaire was sensitive to the effects of pimobendan, an inotropic agent with vasodilator properties, and was insensitive to placebo in patients with moderate-to-severe heart failure.2,3 This report demonstrates the questionnaire's responsiveness to a converting enzyme inhibitor and confirms its insensitivity to placebo.

AB - Patients' perspectives concerning the effects of disease and therapy on their lives have become increasingly important for the assessment of medications in clinical trials. The Minnesota Living with Heart Failure (LIhiFE) questionnaire was developed to systematically and comprehensively assess the patient's perceptions of the effects of heart failure, and its treatment on his or her daily life.1 A valid measure of therapeutic response should be responsive to medications known to benefit patients with heart failure and be insensitive to the effects of placebo. In addition, a valid measure would indicate that patients with overt heart failure have more impairment than do those with left ventricular dysfunction who do not need medications for heart failure. We previously showed that this questionnaire was sensitive to the effects of pimobendan, an inotropic agent with vasodilator properties, and was insensitive to placebo in patients with moderate-to-severe heart failure.2,3 This report demonstrates the questionnaire's responsiveness to a converting enzyme inhibitor and confirms its insensitivity to placebo.

UR - http://www.scopus.com/inward/record.url?scp=0027195028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027195028&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(93)90582-W

DO - 10.1016/0002-9149(93)90582-W

M3 - Article

C2 - 8475878

AN - SCOPUS:0027195028

VL - 71

SP - 1106

EP - 1107

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12

ER -